You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Turn on more accessible mode
Turn off more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Turn on Animations
Sign In
QU Home
العربية
عربي
It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
MWC Economic Forum
Currently selected
Image Viewer
OncoSyn
Page Content
Tag Name: OncoSyn
Next-Generation Nature-Inspired Synthetic Oncology Therapeutics
Discover OncoSyn— a next-generation synthetic small-molecule innovation advancing precision oncology through novel anticancer compounds.
Introduction
OncoSyn is an advanced class of synthetic small-molecule anticancer compounds engineered to target aggressive tumor types.
Developed through innovative medicinal chemistry strategies, OncoSyn introduces a new class of bioactive compounds designed to selectively target key molecular pathways involved in cancer progression. The compounds are designed to enhance therapeutic precision while minimizing off-target toxicity commonly associated with conventional chemotherapy.
Early laboratory evaluations demonstrate promising anticancer activity against aggressive tumor models, positioning OncoSyn as a strong candidate for further preclinical and translational development (TRL 3–4).
Inventors
1
Ashraf Khalil
2
Ala-Eddin Al Moustafa
3
Ola Jihad Hussein
4
Arij Fouzat Hassan
5
Feras Alali
Main Features
Novel Synthetic Anticancer Compounds
Introduces a new class of synthetic small-molecule scaffolds designed for enhanced anticancer activity.
Precision Oncology Targeting
Engineered to selectively target key cancer pathways associated with tumor growth and progression.
Improved Therapeutic Potential
Designed to increase efficacy while reducing toxicity compared with conventional chemotherapy approaches.
Broad Oncology Potential
Demonstrates potential for therapeutic activity across multiple cancer types.
Research-Driven Innovation
Developed through advanced medicinal chemistry and biological validation.
Strategic Opportunities
Oncology Drug Development
Potential advancement into pharmaceutical development pipelines for targeted cancer therapeutics.
Pharmaceutical Partnerships
Opportunity for co-development, licensing, and translational collaboration.
Biotechnology Innovation
Supports next-generation precision medicine initiatives.
Global Cancer Therapeutics Market
Aligned with increasing demand for safer, more effective oncology treatments.
Value Proposition
Next-Generation Oncology Therapeutics
Advancing cancer treatment through innovative synthetic small-molecule drug design.
Precision-Focused Therapeutics
Targets cancer pathways with improved molecular selectivity.
Scalable Drug Development Pathway
Positioned for continued preclinical validation and pharmaceutical advancement.
Strong Commercial Potential
Addresses a major global need for more effective and safer cancer therapies.
Status of the Invention
Intellectual Property Filed
Laboratory Validation Completed
Technology Readiness Level:
TRL 3–4
Invitation to Industry — Collaborate With Us
Join us in shaping the future of precision oncology. OncoSyn is ready for:
Preclinical development partnerships
Pharmaceutical co-development
Biotechnology collaboration
Oncology research alliances
With strong scientific backing from Qatar University, OncoSyn represents a promising step toward safer, smarter cancer therapeutics.
Connect With Us
Innovation Office — Qatar University |
+974-4403-7197 |
QU.IP@qu.edu.qa
IP No:
U.S. Non-Provisional Patent Application No. 18/907,427